DMAC vs LMT · $157.4M cap vs P/E 20, rev $75.05B
DiaMedica Therapeutics Inc (DMAC) versus Lockheed Martin Corporation (LMT) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Lockheed Martin Corporation (LMT) is a aerospace & defense company listed on US. It is led by Jim Taiclet.
DMAC does not have a complete income-statement cache yet.
Latest reported LMT revenue for 2025-12-31 was $75.05B. Net income was $5.02B. Revenue was up 5.6% from 2024-12-31 to 2025-12-31. LMT currently screens at market cap $108.37B and trailing P/E 19.9.
DMAC currently screens at market cap $157.4M. LMT currently screens at market cap $108.37B and trailing P/E 19.9.
Not investment advice. Open the DMAC and LMT stock pages for the full models.
Not investment advice.